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a b s t r a c t
The thermal reaction of Ru3(CO)12 with various carboxylic acids (benzoic, 4-hydroxyphenylacetic,
ferrocenic, stearic, oleic, 4-(octadecyloxy)benzoic) in reﬂuxing tetrahydrofuran, followed by addition of
5-(4-pyridyl)-10,15,20-triphenylporphyrin (L), gives the dinuclear complexes Ru2(CO)4(OOCR)2L2 (1:
R = –C6H5, 2: R = –CH2-p-C6H4OH, 3: R = –C5H4FeC5H5, 4: R = –(CH2)16CH3, 5: R = –(CH2)7CH@CH(CH2)7
CH3, 6: R = –p-C6H4O(CH2)17CH3). Complexes 1–6 were characterised by IR, NMR, and ESI-MS as well
as by elemental analysis. The UV–Vis spectra show the Soret band centred at 417 nm and the Q bands
at 515, 550, 590 and 645 nm, respectively.
1. Introduction
Sawhorse-type ruthenium complexes of the type Ru2(CO)4
(OOCR)2L2, L being a two-electron donor ligand, are well-known
since 1969, when Lewis and co-workers reported their formation
by reﬂuxing Ru3(CO)12 in various carboxylic acids followed by
depolymerisation of the obtained materials in coordinating sol-
vents [1]. These dinuclear complexes were shown later, by a sin-
gle-crystal X-ray structure analysis of Ru2(CO)4(OOCBun)2(PBut3)2,
to possess a Ru2(CO)4 backbone in a sawhorse-type arrangement
with two l2-g2-carboxylato bridges (OOCBun) and two axial
two-electron donor ligands (PBut3) [2]. Since their discovery, a con-
siderable number of such sawhorse-type diruthenium complexes
with carboxylato bridges have been synthesised and used for var-
ious applications ranging from catalysis to materials chemistry [3].
Recently, we found porphyrin derivatives of complexes of the type
Ru2(CO)4(OOCR)2L2 (R = methyl, 5-(4-phenyl)-10,15,20-triphenyl-
porphyrin; L = triphenylphosphine, 1,3,5-triaza-7-phosphatricy-
clo[3.3.1.1]decane, 5-(4-pyridyl)-10,15,20-triphenylporphyrin) to
exhibit considerable phototoxicity speciﬁc for certain cancer cell
lines [4]. Herein, we report the synthesis and characterisation of
six new Ru2(CO)4(OOCR)2L2 sawhorse-type complexes containing
5-(4-pyridyl)-10,15,20-triphenylporphyrin as the axial ligands L.
2. Results and discussion
Dodecacarbonyltriruthenium reacts with the appropriate car-
boxylic acid (benzoic, 4-hydroxyphenylacetic, ferrocenic, stearic,
oleic, 4-(octadecyloxy)benzoic) in reﬂuxing tetrahydrofuran to
give, after addition of the axial ligand 5-(4-pyridyl)-10,15,20-tri-
phenylporphyrin (L), the dinuclear complexes Ru2(CO)4(OOCR)2L2
(1 = Ru2(CO)4(OOCC6H5)2L2; 2 = Ru2(CO)4(OOCCH2-p-C6H4OH)2L2;
3 = Ru2(CO)4(OOCC5H4FeC5H5)2L2; 4 = Ru2(CO)4{OOC(CH2)16CH3}2
L2; 5 = Ru2(CO)4{OOC(CH2)7CH@CH(CH2)7CH3}2L2; 6 = Ru2(CO)4
{OOC-p-C6H4O(CH2)17CH3}2L2) in good yields (73–86%), see
Scheme 1.
2=3Ru3ðCOÞ12 þ RCOOHþ 2L! Ru2ðCOÞ4ðOOCRÞ2L2 þ 4COþ 2H2
All compounds are air-stable dark purple crystalline powders,
sparingly soluble in polar organic solvents, which have been char-
acterised by their infrared, NMR, UV–Vis and mass spectrometry as
well as by their micro-analytical data. All compounds exhibit in the
m(CO) region of the infrared spectrum the characteristic pattern of
the Ru2(CO)4 sawhorse unit [3], which consists of three bands (very
strong; medium; very strong) between 2100 and 1900 cm1
(Table 1). The two carboxylato bridges give rise to two m(OCO)
absorptions between 1550 and 1430 cm1 that correspond to the
asymmetrical and the symmetrical stretching frequencies of the
three-atom oscillators. Moreover, due to the presence of the por-
phyrinic axial ligands, a strong absorption centred at 1595 cm1
corresponding to m(CN) is observed, along with a strong absorption
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for the in-plane N–H deformation at 1215 cm1 and a medium
absorption corresponding to the C–H stretching vibration at
3055 cm1 [5].
The 1H NMR spectra of 1–6 in CD2Cl2 at 23 C display a sim-
ilar signal pattern for the protons of the coordinated 5-(4-pyri-
dyl)-10,15,20-triphenylporphyrin units (L). The N–H protons of
the L axial ligands are observed at d = 2.78 ppm, while two
multiplets at 7.84 and 8.26 ppm are found in the aromatic region
corresponding to the protons of the phenyl rings. In addition,
two broad unresolved singlets of equal intensity for the pyrrole
protons (d = 8.9 and 9.0 ppm) and two doublets for the pyridyl
group (d = 8.4 and 9.5 ppm) are observed. These signals are in
agreement with those found in the mononuclear arene ruthe-
nium porphyrin complexes, [(g6-arene)RuCl2L] (arene = p-cym-
ene, toluene) [6]. In the 13C {1H} NMR spectra, the peaks of
the terminal carbonyl groups and of the carboxylato bridges
are found around 180 and 205 ppm, respectively, in agreement
with those reported in the literature [7–9].
The complexes were characterised by electrospray ionisation
mass spectroscopy in positive mode. In all cases, a major peak at
m/z = 1789.36 for 1, 1849.37 for 2, 1876.21 for 3, 2113.82 for 4,
2109.79 for 5 and 2325.90 for 6, corresponding to [M+H]+ have
been assigned unambiguously on the basis of their characteristic
Ru2 isotope pattern.
Optical absorption spectra of 1–6 as well as the porphyrin li-
gand (L) were acquired in dichloromethane at 105 M concentra-
tion in the range 250–800 nm (Fig. 1). The UV–Vis spectra of all
compounds are characterised by intense absorptions due to the
porphyrin ligands, including the Soret band at around 420 nm
and a series of Q bands between 500 and 700 nm. The four Q bands
are labelled I, II, III and IV on going from longer to shorter wave-
length (Table 2). The data in Table 2 show that the absorption
bands of the uncoordinated 5-(4-pyridyl)-10,15,20-triphenylpor-
phyrin compound remain unchanged upon coordination to the
dinuclear sawhorse unit, thus suggesting no perturbation of the
porphyrin p-orbitals upon coordination.
The ﬂuorescence spectra of L and 1–6 are presented in Fig. 2.
Their ﬂuorescence spectra show after excitation at 350 nm two
red shifted emission peaks, a strong peak at 650 nm and a weak
one at about 705 nm which is the mirror image of the absorp-
tion band. These spectral properties are in good agreement with
those reported for 5-(4-pyridyl)-10,15,20-triphenylporphyrin
[10].
In conclusion, we have synthesised and characterised six new
sawhorse-type complexes containing various carboxylato bridging
ligands and the 5-(4-pyridyl)-10,15,20-triphenylporphyrin axial li-
gands. However, possible biological applications are limited due to
the low solubility of these compounds.
3. Experimental
3.1. General
All manipulations were carried out by routine under nitrogen
atmosphere. Organic solvents were degassed and saturated with
nitrogen prior to use. All carboxylic acids (benzoic, 4-hydroxyphe-
nylacetic, ferrocenic, stearic, oleic and 4-(octadecyloxy)benzoic
acid) were purchased either from Aldrich or Fluka and used as
received, while 5-(4-pyridyl)-10,15,20-triphenylporphyrin was
purchased from TriPorTech GmbH, Germany. Dodecacarbonyltriru-
thenium was prepared according to published methods [11]. NMR
spectra were recorded on a Bruker AvanceII 400 MHz spectrome-
ter. IR spectra were recorded on a Perkin-Elmer 1720X FT-IR spec-
trometer (4000–400 cm1). UV–Vis absorption spectra were
recorded on an Uvikon 930 spectrophotometer using precision
cells made of quartz (1 cm). Fluorescence spectra were recorded
on a Luminescence Spectrometer Perkin-Elmer LS50B using preci-
sion cells made of quartz (1 cm). Mass spectra were obtained in po-
sitive-ion mode with a Bruker FTMS 4.7T BioAPEX II mass
spectrometer, University of Fribourg, Switzerland. Elemental anal-
yses were performed by the Mikroelementarisches Laboratorium,
ETH Zürich or the Laboratory of Pharmaceutical Chemistry, Univer-
sity of Geneva, Switzerland.
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Scheme 1. Synthesis of the dinuclear complexes Ru2(CO)4(OOCR)2L2 (1–6).
Table 1
Infrared data of complexes 1–6 (CH2Cl2).
Complex m(CO) (cm1) m(CN)
(cm1)
m(OCO) (cm1)
1 2026.18 vs, 1976.90 m,
1941.93 s
1598.47 s 1548.55 s, 1440.36
m
2 2026.30 vs, 1976.75 m,
1942.01 vs
1598.26 s 1547.63 s, 1439.77
m
3 2026.12 vs, 1976.77 m,
1941.53 vs
1598.43 s 1555.54 s, 1439.83
m
4 2025.14 vs, 1977.93 m,
1940.76 vs
1594.67 s 1552.05 s, 1439.75
m
5 2025.34 vs, 1977.85 m,
1940.69 vs
1594.23 s 1554.12 s, 1441.47
m
6 2025.23 vs, 1977.82 m,
1940.63 vs
1594.58 s 1555.71 s, 1438.68
m
2
3.2. General method for the preparation of complexes 1–6
A solution of Ru3(CO)12 (50 mg, 0.07 mmol) and the appropriate
carboxylic acid (0.22 mmol: 28 mg, 1; 34 mg, 2; 52 mg, 3; 62 mg,
4; 62 mg, 5; 86 mg, 6) in dry tetrahydrofuran (25 ml) was heated
at 120 C in a pressure Schlenk tube for 18 h. Then the solvent
was evaporated to give a purple or brown residue which was dis-
solved in tetrahydrofuran and 3 equiv. of 5-(4-pyridyl)-10,15,20-
triphenylporphyrin (0.22 mmol, 135 mg) was added. The solution
was stirred at room temperature for 3 h, and the product was iso-
lated by precipitation upon addition of diethyl ether. The precipi-
Fig. 1. Optical spectra of L and complexes 1–6 at 105 M concentration in CH2Cl2 solution at room temperature.
Table 2
UV–Vis data for L and complexes 1–6 at 105 M concentration in CH2Cl2 solution at
room temperaturea.
Compound Soret Visible IV Visible III Visible II Visible I
1 413 (331) 514 (37.7) 549 (13.7) 589 (9.6) 645 (6.0)
2 416 (333) 515 (21.2) 550 (15.1) 590 (10.2) 645 (7.6)
3 415 (341) 515 (40.1) 550 (18.2) 590 (11.9) 645 (8.5)
4 417 (332) 515 (31.4) 550 (14.1) 590 (9.6) 645 (7.1)
5 414 (340) 515 (41.9) 550 (18.1) 590 (11.3) 645 (8.0)
6 416 (335) 515 (35.2) 550 (15.2) 590 (9.2) 645 (6.6)
L 415 (313) 514 (19.0) 548 (6.1) 589 (4.4) 645 (2.5)
a kmax (extinction coefﬁcient (e  103, M1 cm1)).
Fig. 2. Fluorescence emission spectra of L and complexes 1–6 at 105 M concentration in CH2Cl2 solution upon excitation at 350 nm at room temperature.
3
tate was ﬁltered and dried under vacuum to give air-stable purple
crystalline powders.
3.2.1. Ru2(CO)4(OOCC6H5)2(L)2: 1
Yield: 339 mg (86%). 1H NMR (400 MHz, CD2Cl2): d = 2.76 (s,
4H, NH), 7.43–7.50 (m, 10H, C6H5), 7.82–7.85 (m, 18H, C6H5),
8.26–8.30 (m, 12H, C6H5), 8.54 (d, 4H, NC5H4, 3JH–H = 6 Hz), 8.93
(br s, 8H, CHporph), 9.11 (br s, 8H, CHporph), 9.47 ppm (d, 4H,
NC5H4, 3JH–H = 6 Hz). 13C{1H} NMR (100 MHz, CD2Cl2): d = 120.95,
126.89, 128.18, 129.94, 130.73, 130.98, 133.56, 134.75, 142.05,
152.43, 179.33, 197.60, 204.77 ppm. IR (CH2Cl2): m(porphyrin N–H)
1214.19 s, m(OCO) 1440.36 m, m(OCO) 1548.55 s, m(CN) 1598.47 s,
m(CO) 1941.93 vs, m(CO) 1976.90 m, m(CO) 2026.18 vs, m(aromatic C–H)
3052.34 m, cm1. ESI-MS: m/z = 1789.36 [M+H+]. Anal. Calc. for
C104H68N10O8Ru2: C, 69.87; H, 3.83; N, 7.83. Found: C, 69.66; H,
3.95; N, 7.72%.
3.2.2. Ru2(CO)4(OOCCH2-p-C6H4OH)2(L)2: 2
Yield: 349 mg (85%). 1H NMR (400 MHz, CD2Cl2): d = 2.79 (s,
4H, NH), 3.62 (s, 4H, –CH2-p-C6H4–OH), 6.57 (d, 4H, C6H4), 7.02
(d, 4H, C6H4), 7.77–7.83 (m, 18H, C6H5), 8.21–8.26 (m, 12H,
C6H5), 8.88 (br s, 8H, CHporph), 8.92 (br s, 8H, CHporph), 8.94 (d,
4H, NC5H4, 3JH–H = 6 Hz), 9.40 ppm (d, 4H, NC5H4, 3JH–H = 6 Hz).
13C{1H} NMR (100 MHz, CD2Cl2): d = 42.92, 53.93, 114.95, 115.41,
120.94, 121.45, 126.94, 128.02, 128.82, 130.58, 130.68, 130.72,
134.65, 134.68, 141.92, 150.24, 152.04, 154.33, 185.49,
204.70 ppm. IR (CH2Cl2): m(porphyrin N–H) 1214.55 s, m(OCO) 1439.77
m, m(OCO) 1547.63 s, m(CN) 1598.26 s, m(CO) 1942.01 vs, m(CO)
1976.75 m, m(CO) 2026.30 vs, m(aromatic C–H) 3055.74 m, cm1. ESI-
MS: m/z = 1849.37 [M+H+]. Anal. Calc. for C106H72N10O10Ru2: C,
68.90; H, 3.93; N, 7.58. Found: C, 68.74; H, 4.06; N, 7.43%.
3.2.3. Ru2(CO)4(OOCC5H4FeC5H5)2(L)2: 3
Yield: 342 mg (77%). 1H NMR (400 MHz, CD2Cl2): d = 2.76 (s,
4H, NH), 4.27 (s, 10H, CHFc), 4.33 (d, 4H, CHFc), 4.92 (t, 4H, CHFc),
7.81–7.87 (m, 18H, C6H5), 8.26–8.30 (m, 12H, C6H5), 8.52 (d, 4H,
NC5H4, 3JH–H = 6 Hz), 8.93 (br s, 8H, CHporph), 9.06 (br s, 8H, CHporph),
9.43 ppm (d, 4H, NC5H4, 3JH–H = 6 Hz). 13C{1H} NMR (100 MHz,
CD2Cl2): d = 29.77, 69.86, 70.54, 70.76, 120.95, 121.45, 126.89,
126.94, 128.03, 130.79, 134.66, 134.67, 141.94, 150.34, 186.29,
204.43 ppm. IR (CH2Cl2): m(porphyrin N–H) 1214.23 s, m(OCO) 1439.83
m, m(OCO) 1555.54 s, m(CN) 1598.43 s, m(CO) 1941.53 vs, m(CO)
1976.77 m, m(CO) 2026.12 vs, m(aromatic C–H) 3053.61 m, cm1. ESI-
MS: m/z = 1876.21 [M+H+]. Anal. Calc. for C102H67Fe2N10O8Ru2: C,
65.36; H, 3.60; N, 7.47. Found: C, 65.35; H, 3.66; N, 7.33%.
3.2.4. Ru2(CO)4(OOC(CH2)16CH3)2(L)2: 4
Yield: 342 mg (73%). 1H NMR (400 MHz, CD2Cl2): d = 2.78 (s,
4H, NH), 0.75 (t, 6H, –(CH2)16–CH3), 0.85–1.46 (m, 56H, –(CH2)2–
(CH2)14–CH3), 1.79 (q, 4H, –CH2–CH2–(CH2)14–CH3), 2.56 (t, 4H, –
CH2–CH2–(CH2)14–CH3), 7.80–7.86 (m, 18H, C6H5), 8.25–8.28 (m,
12H, C6H5), 8.40 (d, 4H, NC5H4, 3JH–H = 6 Hz), 8.92 (br s, 8H, CHporph),
9.01 (br s, 8H, CHporph), 9.26 ppm (d, 4H, NC5H4, 3JH–H = 6 Hz).
13C{1H} NMR (100 MHz, CD2Cl2): d = 13.85, 22.62, 26.58, 29.18,
29.44, 29.47, 29.52, 29.54, 29.61, 29.73, 29.82, 31.81, 37.21,
120.92, 126.88, 126.92, 128.02, 130.78, 134.66, 141.96, 150.26,
187.52, 204.86 ppm. IR (CH2Cl2): m(porphyrin N–H) 1214.30 s, m(OCO)
1439.75 m, m(OCO) 1552.05 s, m(CN) 1594.67 s, m(CO) 1940.76 vs,
m(CO) 1977.93 m, m(CO) 2025.14 vs, m(aromatic C–H) 3054.37 m, cm1.
ESI-MS: m/z = 2113.82 [M+H+]. Anal. Calc. for C126H128N10O8Ru2:
C, 71.64; H, 6.11; N, 6.63. Found: C, 71.36; H, 5.94; N, 6.55%.
3.2.5. Ru2(CO)4(OOC(CH2)7CH@CH(CH2)7CH3)2(L)2: 5
Yield: 386 mg (83%). 1H NMR (400 MHz, CD2Cl2): d = 2.79 (s,
4H, NH), 0.75 (t, 6H, –(CH2)7–CH@CH–(CH2)7–CH3), 0.85–1.43 (m,
44H, –CH2–(CH2)5–CH2–CH@CH–CH2–(CH2)6–CH3), 1.77 (m, 8H, –
(CH2)6–CH2–CH@CH–CH2–(CH2)6–CH3), 2.54 (t, 4H, –CH2–(CH2)6–
CH@CH–(CH2)7–CH3), 4.99 (m, 4H, –CH2–(CH2)6–CH@CH–(CH2)7–
CH3), 7.81–7.86 (m, 18H, C6H5), 8.25–8.28 (m, 12H, C6H5), 8.39
(d, 4H, NC5H4, 3JH–H = 6 Hz), 8.92 (br s, 8H, CHporph), 9.01 (br s,
8H, CHporph), 9.25 ppm (d, 4H, NC5H4, 3JH–H = 6 Hz). 13C{1H} NMR
(100 MHz, CD2Cl2): d = 22.63, 26.57, 29.29, 29.42, 29.51, 29.64,
29.75, 29.80, 31.82, 37.21, 115.38, 120.92, 121.43, 126.88, 126.93,
128.02, 130.10, 131.51, 131.62, 134.66, 141.96, 150.26, 187.55,
204.83 ppm. IR (CH2Cl2): m(porphyrin N–H) 1214.25 s, m(OCO) 1441.47
m, m(OCO) 1554.12 s, m(CN) 1594.23 s, m(CO) 1940.69 vs, m(CO)
1977.85 m, m(CO) 2025.34 vs, m(aromatic C–H) 3055.32 m, cm1. ESI-
MS: m/z = 2109.79 [M+H+]. Anal. Calc. for C126H124N10O8Ru2: C,
71.77; H, 5.93; N, 6.64. Found: C, 71.54; H, 5.97; N, 6.49%.
3.2.6. Ru2(CO)4(OOC-p-C6H4O(CH2)17CH3)2(L)2: 6
Yield: 432 mg (84%). 1H NMR (400 MHz, CD2Cl2): d = 2.77 (s,
4H, NH), 0.82 (t, 6H, –p-C6H4–O–(CH2)17–CH3), 1.21 (m, 56H, –p-
C6H4–O–(CH2)3–(CH2)14–CH3), 1.40 (q, 4H, –p-C6H4–O–CH2–CH2–
CH2–), 1.73 (q, 4H, –p-C6H4–O–CH2–CH2–), 3.95 (t, 4H, –p-C6H4–
O–CH2–CH2–), 6.89 (d, 4H, C6H4), 7.82–7.85 (m, 18H, C6H5), 8.18
(d, 4H, C6H4), 8.26–8.30 (m, 12H, C6H5), 8.51 (d, 4H, NC5H4, 3JH–H
= 6 Hz), 8.93 (br s, 8H, CHporph), 9.06 (br s, 8H, CHporph), 9.45 ppm
(d, 4H, NC5H4, 3JH–H = 6 Hz). 13C{1H} NMR (100 MHz, CD2Cl2):
d = 22.72, 26.02, 29.63, 29.65, 29.68, 29.72, 31.95, 113.81, 120.67,
126.90, 126.94, 128.04, 134.68, 150.43, 187.56, 204.64 ppm. IR
(CH2Cl2): m(porphyrin N–H) 1214.29 s, m(OCO) 1438.68 m, m(OCO)
1555.71 s, m(CN) 1594.58 s, m(CO) 1940.63 vs, m(CO) 1977.82 m, m(CO)
2025.23 vs, m(aromatic C–H) 3055.42 m, cm1. ESI-MS: m/z = 2325.90
[M+H+]. Anal. Calc. for C140H140N10O10Ru2: C, 72.33; H, 6.07; N,
6.02. Found: C, 72.26; H, 5.88; N, 5.94%.
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